Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-VIEW study of certolizumab pegol for prevention of anterior uveitis flares in axial spondyloarthritis
NL-OMON46252Phase 4Active, not recruiting
- Sponsor
- UCB
- Start
- Mar 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of certolizumab pegol in axial spondyloarthritis (axSpA) and cyclitis, sponsored by UCB. Primary endpoint: Count of distinct anterior uveitis flares during treatment. Started Mar 2017; status: active, not recruiting.
02
Drugs
certolizumab pegol
03
Conditions
axial spondyloarthritis (axSpA)cyclitis
Beyond the preview
Go deeper on NL-OMON46252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46252.